Company Analysis

Evolus, Inc. (EOLS)

Nasdaq: EOLS · Pharmaceutical Preparations · Newport Beach, CA · filing with the SEC since 2013
Grade6.2
◀ Past 7.5● Present 6.3▶ Future 4.7
1 est.

Who runs Evolus, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Moatazedi David
President and Chief Executive Officer. First filing May 2018, latest Sep 4, 2026, 25 filings in all.
Officers reporting now
4
of 9 people with a filing in the last fifteen months
Directors reporting now
5
20 people on the record since 2018
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Moatazedi DavidPresident and Chief Executive OfficerMay 2018Sep 4, 20264 · $1.7M
Avelar RuiChief Medical Officer and Head of Research & DevelopmentFeb 2018Mar 20, 20263 · $200,000
Mitchell TatjanaChief Financial OfficerSep 2025Feb 19, 2026none
Yamagishi-Dressler TomokoChief Marketing OfficerAug 2023Aug 26, 2025none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Gill David NdirectorFeb 2018Feb 19, 2026none
Malik VikramdirectorFeb 2018Feb 19, 2026none
Parschauer Karah HerdmandirectorJul 2019Feb 19, 2026none
Stewart BradydirectorJan 2022Feb 19, 2026none
White Albert G IIIdirectorJul 2024Feb 19, 2026none
Earlier names on the record14, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton EOLS · research, not advice